WillItSurvive
Pharma and healthcare groups · United States

Gilead Sciences

gilead.com ↗

Gilead makes HIV, liver, and cancer drugs, led by Biktarvy and new PrEP shot Yeztugo.

Hard to displace
Assessed 20 July 2026 · Evidence as of 20 July 2026
Strong structural protection; the business model survives ai pressure.
On the recordSince 20 July 2026 · Checkable from 2026 (post May 6 oral argument) · Every call on the record Checkpoint: California Supreme Court ruling on TDF/Truvada 'delayed safer drug' liability theory
The call

Gilead's patents, regulatory approvals, and global health distribution deals keep its HIV franchise growing while a liability ruling and rival injectables loom as the main watch points.

Gilead Sciences makes prescription medicines, especially HIV treatments that are approved by the FDA and protected by patents lasting years into the future. It is hard to copy because each new drug requires expensive clinical trials, FDA approval, and deals with hospitals and governments (like PEPFAR) that take years to build, though competitors like ViiV Healthcare and Merck are fighting for HIV market share with their own approved drugs. The biggest wildcard is a California court case starting in May 2026 about whether Gilead delayed releasing a safer HIV drug, which could open the door to thousands of lawsuits and shake investor confidence, even though it would not immediately threaten the company's survival.

Why
01
AI pressure: None apparent. AI tools like Genesis Therapeutics' GEMS platform speed up Gilead's own drug discovery, they don't threaten its patented drug sales. Could AI do the core job? Unlikely.
02
Bigger players: ViiV Healthcare (GSK, Pfizer, Shionogi joint venture). ViiV's Apretude injectable PrEP already competes for the same long-acting HIV prevention patients Yeztugo is chasing. Could a giant copy it? No, they are blocked.
03
What protects it. Patents on Biktarvy and lenacapavir, FDA approvals, and deep ties with PEPFAR and Global Fund distribution networks.
What would change this call
California Supreme Court ruling on TDF/Truvada liability theory (case argued May 6, 2026). A broad ruling against Gilead could open large mass-tort liability exposure.
FDA decision on once-weekly oral lenacapavir by PDUFA date February 2, 2027. Approval would extend Gilead's HIV franchise; rejection would weaken its pipeline defense.
Yeztugo sales figures versus ViiV's Apretude (cabotegravir) in 2026 to 2027 earnings reports. Shows whether Gilead's injectable PrEP is gaining or losing share to ViiV.
Key numbers
  • FY2025 total revenue $29.443B (2025-12-31)
  • Biktarvy sales $14.3B, up 7% YoY (2025-12-31)
  • Yeztugo FY2026 guidance raised to ~$1.0B (2026-05-06)
Named risks
  • California Supreme Court could open uncapped mass-tort liability on TDF/Truvada 'delayed safer drug' theory. Severity: high
  • Biktarvy concentration, near half of product sales on one drug, ahead of Yeztugo scaling. Severity: medium
  • Once-weekly oral lenacapavir could fail at February 2, 2027 PDUFA date. Severity: medium
  • Newly acquired pipeline (Arcellx, Tubulis, Ouro) must replace Biktarvy revenue before its patent cliff in early 2030s. Severity: medium
  • Ongoing HIV antitrust MDL and Third Circuit qui tam appeal add legal exposure. Severity: low
Rivals, as read in July 2026
RivalDirectionEvidence
ViiV HealthcarecontestingViiV holds ~32% global HIV market share with Apretude (cabotegravir) competing against Yeztugo launched June 2025
MerckcontestingMerck co-develops long-acting HIV drugs and competes in oncology alongside Gilead's Tempus AI partnership expanded April 2026
Johnson & Johnson/JanssencontestingJ&J's Symtuza and Prezista compete in HIV treatment; also named in HIV antitrust MDL alongside Gilead
AstraZeneca, BMS, GSKcontestingOncology rivals also partnering with Tempus AI's Lens platform as of April 2026
Questions people ask
Is Gilead Sciences profitable in 2026?
Gilead posted FY2025 revenue of $29.443 billion and raised FY2026 product sales guidance to $30.0-30.4 billion in May 2026, though GAAP EPS guidance is -$1.05 to -$0.65 due to about $9.50/share in one-time M&A and IPR&D transaction charges from 2026 acquisitions.
Is Gilead laying off employees?
Gilead's headcount fell to 17,000 employees as of December 31, 2025, down 600 (-3.4%) from 17,600 in 2024, continuing a decline from 18,000 in 2023, even as it posted 1,323 active job postings in 2025, a 43.1% increase year over year.
Could AI replace Gilead Sciences' business?
No. Gilead's revenue comes from FDA-approved, patent-protected drugs like Biktarvy ($14.3B in FY2025) and Yeztugo, protected by regulatory approval, clinical trial data, and payer relationships. AI partnerships with Genesis Therapeutics, Terray Therapeutics, and Tempus (expanded April 2026) only accelerate upstream drug discovery, not revenue generation.
Who is Gilead Sciences' biggest competitor in HIV drugs?
ViiV Healthcare, a joint venture of GSK, Pfizer, and Shionogi, holds roughly 32% of the global HIV market and is Gilead's closest rival, competing directly against Gilead's new Yeztugo injectable PrEP with its own long-acting cabotegravir product, Apretude.
What is Gilead's flagship drug and how big is it?
Biktarvy is Gilead's flagship HIV treatment, generating $14.3 billion in FY2025 revenue, up 7% year over year, and representing roughly half of Gilead's total product sales as of December 31, 2025.
What is Yeztugo and how is it performing?
Yeztugo (lenacapavir) is Gilead's twice-yearly injectable HIV prevention drug, FDA-approved June 18, 2025, and EU-authorized August 25, 2025. Gilead raised its FY2026 Yeztugo sales guidance to about $1.0 billion in May 2026, up from an earlier ~$0.8 billion estimate.
Timeline
  • 2026-06-15FDA accepts sNDA for once-weekly oral lenacapavir PrEP tablet, PDUFA date set for February 2, 2027
  • 2026-06-03Gilead and Lakefront complete acquisition of Ouro Medicines for autoimmune T-cell engager pipeline
  • 2026-05-20Gilead completes acquisition of Tubulis, adding oncology antibody-drug conjugate platform
  • 2026-05-06California Supreme Court hears oral argument on TDF/Truvada mass-tort liability theory
  • 2026-05-06Gilead reports Q1 2026 revenue of $6.96B (+4.4% YoY) and raises FY2026 guidance
  • 2026-04-09Gilead expands multi-year enterprise AI deal with Tempus AI for oncology data platform Lens
  • 2025-09-18CDC endorses Yeztugo (lenacapavir) for HIV prevention; PEPFAR/Global Fund access deals target 2 million people
  • 2025-08-25European Commission authorizes Yeytuo (lenacapavir) for HIV prevention
  • 2025-06-18FDA approves Yeztugo (lenacapavir) as first twice-yearly injectable HIV PrEP
  • 2024-09-18Gilead partners with Genesis Therapeutics on GEMS AI drug discovery platform, $35M for three targets
Revision history
20 July 2026
First assessed. Hard to displace. The text above is fixed as of this date and is not edited afterwards.
In the same band
Vertex PharmaceuticalsTenet HealthcareIntuitive Surgical
More in Pharma and healthcare groups →
Sources